Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Nephros Inc(NEPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NEPH
11/06/2026: NEPH (2-star) is currently NOT-A-BUY. Pass it for now.
Nephros Inc is a medical technology company specializing in high-performance water filtration and hemodiafiltration solutions. Its primary strength lies in its specialized ultrafiltration products, which address critical water safety and infection control needs in hospital settings. The company’s growth story hinges on the broader adoption of these safety protocols and successful expansion into commercial water markets. However, investors face risks from larger, well-capitalized competitors, execution challenges, and the potential for regulatory shifts. Nephros is generally more suited to growth-focused investors who can tolerate volatility, and it is not currently a dividend-paying stock. Investors should monitor hospital capital expenditure trends and new partnership developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential in the niche infection control market but lacks the scale of larger peers. |
| Momentum investor | Weak fit | Trading volume and price action do not typically provide the consistent trend signals favored by momentum strategies. |
| Value investor | Mixed fit | Valuation is sensitive to the company's ability to maintain revenue growth and achieve consistent profitability. |
| Dividend investor | Weak fit | Nephros does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | High price volatility and small-cap status present risks inappropriate for low-risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock's small-cap nature often results in significant price swings. |
| Valuation risk | Medium / high | Investors must pay close attention to revenue multiples given the company's growth-dependent valuation. |
| Competition risk | High | Large conglomerates like Pentair have greater resources for price and feature competition. |
| Business quality | Medium | While the technology is specialized, the firm's small scale limits its market influence. |
| Dividend income | Low / none | Investors receive no cash return from dividends. |
| Execution risk | Medium | Meeting sales targets and maintaining margin control is critical for long-term viability. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 225.45% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 30.33M USD | Price to earnings Ratio 16.41 | 1Y Target Price 6.25 |
Price to earnings Ratio 16.41 | 1Y Target Price 6.25 | ||
Volume (30-day avg) 52.3K shares | Beta 1.75 | 52 Weeks Range 2.66 - 6.42 | Updated Date 11/07/2026 |
52 Weeks Range 2.66 - 6.42 | Updated Date 11/07/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.17 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Water Filtration Systems | Point-of-use and point-of-entry ultrafilters and related components. | The company generates steady revenue through the replacement of filtration cartridges in hospitals. |
| Renal Therapy | Specialized hemodiafiltration equipment and consumables. | A secondary revenue source involving specialized medical equipment for kidney treatment. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When After Market | Estimate 0.02 | Actual 0.05 |
Profitability
Profit Margin 8.38% | Operating Margin (TTM) 20.16% |
Management Effectiveness
Return on Assets (TTM) 7.33% | Return on Equity (TTM) 16.1% |
Valuation
Trailing PE 16.41 | Forward PE - | Enterprise Value 26.66M | Price to Sales(TTM) 1.46 |
Enterprise Value 26.66M | Price to Sales(TTM) 1.46 | ||
Enterprise Value to Revenue 1.44 | Enterprise Value to EBITDA 15.91 | Shares Outstanding 10.87M | Shares Floating 8.93M |
Shares Outstanding 10.87M | Shares Floating 8.93M | ||
Percent Insiders 19.45 | Percent Institutions 17.82 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.